Annual report
Annual report · Medico Remedies Limited has informed the Exchange regarding Notice of undefined to be held on September 22, 2026
Source: Nse
Medico Remedies Limited (MEDICO)
Small CapPharma stocks · Small cap · NSE
Medico Remedies Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result13 Aug, 05:33 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
57Neutralfull bear SMA stack · SMA20 -38.7% / mo · RSI oversold · MACD + · near 52W low · sector +4.9pp vs Nifty 500 (3M)
Stock trend: 28
Sector RS: 100
Sector 3M: -0.7% vs Nifty 500 -5.6%
Pharma FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
MEDICOD candles · FIT view-49.5%Latest close ₹20.78 on 2026-10-21
Bar
-4.7%
RSI
22
MACD hist
0.42
52W pos
1%
2026-10-21O ₹21.80H ₹22.00L ₹20.62C ₹20.78Vol 1.4L sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
MEDICONifty PharmaNifty 500
- MEDICO
- -46.2%
- Nifty 500
- -6.5%
- Nifty Pharma
- -2.0%
- Vs Nifty 500
- -39.7 pp
Chart stats
21 Oct 2026- From 52W high
- -63.5%
- 52W range position
- 1%
- ATR (14)
- 8.8%
- Volume vs 20D
- 0.20x
- Avg traded value
- ₹1.6 Cr
- 20D price channel
- ₹20.5 - ₹34.7
₹56.9
₹20.5 - ₹56.9
₹1.8
Latest completed session
20-session average
96.6% annualized volatility
Research snapshot
What the evidence says now
Investable fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is consistent.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · UNDERVALUED65
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Good62
Revenue +81.4% · PAT +38.5% YoY
Technical
Neutral57
Price trend and sector-relative-strength timing.
Valuation
Legacy model+72.4%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence85
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Good · 62/100Rev +81% YoY · PAT +38% YoY · +22% QoQ · margin compression
Filed 13 Aug 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹69.4 Cr | +81.4% | +22.2% |
| EBITDA | ₹3.3 Cr | +17.0% | -53.8% |
| Operating margin | 4.8% | -261 bps | -783 bps |
| PAT | ₹2.5 Cr | +38.5% | -57.0% |
| PAT margin | 3.6% | -113 bps | -669 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 13.00
- P/B
- 2.38
- EV/EBITDA
- 9.48
- Market Cap
- 180.00Cr
Profitability
- ROE
- 19.00%
- ROCE
- 23.30%
- ROA
- 9.15%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 11.00%
- EPS 5Y
- 38.00%
- Revenue 3Y
- 14.00%
- EPS 3Y
- 22.00%
Balance Sheet
- Debt/Equity
- 0.25
- Interest Coverage
- 9.00×
- Altman Z
- 4.07
- Book Value
- 9.10
Cash Flow
- FCF Yield
- 0.56%
- FCF Positive Y
- 5/5
- OCF
- 6.00 Cr
- EPS TTM
- 1.67
Shareholding
- Promoter Hold
- 61.38%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 3%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 69.4+22.2% vs prev
Net Profit
₹ CrLatest: 2.5-57.0% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term trend down. RSI 22. Wait for confirmation.
- Price < SMA20 < SMA50 < SMA200 — full bearish stack.
- SMA20 falling (~63.0% over last month) — short-term momentum negative.
- RSI(14) at 22 — oversold zone; bounce conditions.
- MACD above signal, histogram expanding — bullish momentum building.
- Within 5% of 52-week low — testing support.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
3
RS percentile
Stage 4 Downtrend
1M return
-39.0%
3M return
-46.2%
6M return
-50.4%
1Y return
-56.8%
RS 1D
0
RS 20D
-17
Sector rank
#1
Industry rank
#14
Stage evidence
- Price is 46.9% below the 30-week proxy.
- The 50-DMA is below the 30-week proxy and its slope is falling -5.8%.
- Both 3-month and 6-month returns are negative.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
21 Oct 2026Value 45.1-2.13%
RS vs Nifty 50045
Valuation & peers
U-Score 65 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 65 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Deep Value
Fundamental score breakdown
U band · UNDERVALUEDValuation22/30
Growth16/25
Quality14/20
Balance Sheet11/15
Cash Flow4/10
Piotroski
7/9 (+5)
Penalties
-7
Raw sum
65
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
65/100 · legacy band UNDERVALUED
Positive drivers
- Piotroski is strong at 7/9.
- Fair-value margin of safety is positive at 72.4%.
- Valuation contributes 22/30 to the score.
Main drags
- Penalty bucket subtracts 7 points.
- Cash flow is weaker at 4/10; verify the latest quarterly trend.
- Growth is weaker at 16/25; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
13.0
PB
2.4
EV/EBITDA
9.5
ROE
19.0%
ROCE
23.3%
FCF Yield
0.6%
Debt/Equity
0.3
MoS
+72.4%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
65
Previous: 65
Legacy U-Score band
UNDERVALUED
Previous: UNDERVALUED
Margin of safety
+72.4%
Previous: +71.5%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
62
62
62
65
62
65
65
65
65
65
65
65
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹18.49
-12.4% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹75.15
+72.4% MoS
PEG
0.41
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
NATCAPSUQ
Small
Natural Capsules Limited
Healthcare Services
match 166
52
13.5
6.5%
+71%
FAIR VALUE
NECLIFE
Small
Nectar Lifesciences Limited
Healthcare Services
match 163
25
—
-31.3%
—
OVERVALUED
LOTUSEYE
Small
Lotus Eye Hospital and Institute Limited
Healthcare Services
match 160
13
1504.0
0.1%
-161992%
OVERVALUED
LYKALABS
Small
Lyka Labs Limited
Healthcare Services
match 159
20
—
-10.2%
—
OVERVALUED
VINEETLAB
Small
Vineet Laboratories Limited
Healthcare Services
match 157
4
65.0
3.7%
-1551%
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Medico Remedies Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
85Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 98th percentile of the scored universe and 98th percentile within Pharma. No major sub-score weakness stands out.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
5 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
98th percentile
overall median 67 · Pharma: 98th pctile, median 70 · Small: 99th pctile, median 66
Evidence depth
Financial-only
5 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Can support position sizing if valuation and trend also agree.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
77
strong · profit to cash conversion
Balance sheet
89
strong · leverage and solvency
Discipline
90
strong · capital discipline
Results
87
strong · quarterly consistency
Trust positives
- ▸Promoter holding is 61.4%.
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 0.3%.
- ▸5 years of positive FCF.
Trust risks
- ▸No major Trust Lite risk flags.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Medico Remedies Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order 5 Aug - Medico Remedies won USD 1.406 million government supply order from PROMESE/CAL, Dominican Republic, to be completed in 3 months.
Source: Bse
Credit rating
Credit-rating report · Medico Remedies Limited has informed the Exchange about Credit Rating
Source: Nse
Credit rating
Announcement under Regulation 30 (LODR)-Credit Rating 29 Jun - CRISIL reaffirmed Medico Remedies' BBB-/Stable ratings on ₹42 crore bank facilities, enhanced from ₹19 crore.
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2025
Source: Bse
Annual report
Submission Of Annual Report For The Financial Year 2025-26 Along With The Notice Of The 32Nd Annual General Meeting 29 Aug
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.